DCN Dx and Mapp Biopharmaceutical Announce Subcontract
Addressing the Need for the Rapid Non-subjective, Digitized Detection of Ebola and Ebola Family Viruses
Excerpt from the Press Release:
CARLSBAD, Calif., Feb. 1, 2023 /PRNewswire/ — DCN Dx, a global leader in the end-to-end development, manufacturing, and commercialization of point-of-use tests, today announced a subcontract with Mapp Biopharmaceutical, Inc., a developer of novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense.
The subcontract covers the development, optimization, and deployment of a digitized lateral flow assay to detect circulating Sudan ebolavirus (SUDV) antigen for real-time use in nonclinical studies taking place within biosafety level 4 (BSL4/ABSL4) containment laboratories.
“DCN Dx is proud to partner with Mapp Biopharmaceutical to develop medical countermeasures for SUDV,” said Mitzi Rettinger, DCN Dx’s Chief Revenue Officer. “This digitized lateral flow assay will be among the first to offer rapid, cage-side detection of SUDV antigens in nonclinical studies.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?